Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-Intensity Statin Use and LDL-C Control

J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al

Guideline-directed use of high-intensity statin therapy (HIST) significantly increased over the past 10 years and coincided with decreased population low-density lipoprotein cholesterol (LDL-C) levels among adults with atherosclerotic cardiovascular disease (ASCVD) enrolled in clinical pharmacy cardiac risk reduction service. The cross-sectional studies were performed over time, comprised of 18,006 adults with both acute and chronic ASCVD, to assess trends in statin use and LDL-C levels from 2007 to 2016. Researchers found:

  • The use of statin therapy (any intensity) remained relatively consistent throughout the study period.
  • The proportion of patients receiving HIST increased to a peak of 67%.
  • Use of prescription non-statin lipid-lowering therapy decreased from 25% to 2%.
  • The proportion of patients achieving LDL-C <70 mg/dL increased from 39% to 54%.

Citation:

Lamprecht Jr DG, Shaw PB, King JB, Hogan K, Olson KL. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. [Published online ahead of print April 26, 2018]. J Clin Lipidol. doi:10.1016/j.jacl.2018.04.007.